» Articles » PMID: 38948079

STAT3 Drives the Malignant Progression of Low-grade Gliomas Through Modulating the Expression of STAT1, FOXO1, and MYC

Overview
Specialty Biology
Date 2024 Jul 1
PMID 38948079
Authors
Affiliations
Soon will be listed here.
Abstract

Low-grade glioma (LGG) is a prevalent and lethal primary brain malignancy, with most patients succumbing to recurrence and progression. The signal transducer and activator of transcription (STAT) family has long been implicated in tumor initiation and progression. However, a comprehensive evaluation of the expression status and overall function of STAT genes in LGG remains largely unreported. In this study, we investigated the association between the expression of STAT family genes and the progression of LGG. Through a comprehensive analysis that combined bioinformatics screening and validation assays, we determined that STAT1, STAT3, and STAT5A were upregulated and contributed to the malignant progression of LGG. Notably, our findings suggest that STAT3 is a critical prognostic marker that regulates the progression of LGG. STAT3 emerged as the most significant prognostic indicator governing the advancement of LGG. Additionally, our inquiry into the STAT3-binding proteins and differentially expressed-correlated genes (DEGs) revealed that STAT3 played a pivotal role in the progression of LGG by stimulating the expression of STAT1, FOXO1, and MYC. In summary, our recent study conducted a thorough analysis of the STAT family genes and revealed that directing therapeutic interventions towards STAT3 holds potential as a viable strategy for treating patients with LGG.

Citing Articles

Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit.

Deng J, Li H, Liu Z, Liang J, Ren Y, Zeng Y Acta Pharmacol Sin. 2025; .

PMID: 39939802 DOI: 10.1038/s41401-025-01481-2.


Graph Attention Network-Based Prediction of Drug-Gene Interactions of Signal Transducer and Activator of Transcription (STAT) Receptor in Periodontal Regeneration.

Chatterjee S, Yadalam P Cureus. 2024; 16(9):e68764.

PMID: 39376880 PMC: 11456413. DOI: 10.7759/cureus.68764.

References
1.
Maurer B, Kollmann S, Pickem J, Hoelbl-Kovacic A, Sexl V . STAT5A and STAT5B-Twins with Different Personalities in Hematopoiesis and Leukemia. Cancers (Basel). 2019; 11(11). PMC: 6895831. DOI: 10.3390/cancers11111726. View

2.
Doucette T, Kong L, Yang Y, Ferguson S, Yang J, Wei J . Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012; 14(9):1136-45. PMC: 3424209. DOI: 10.1093/neuonc/nos139. View

3.
Mathur R, Zhang Y, Grimmer M, Hong C, Zhang M, Bollam S . MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020; 22(11):1580-1590. PMC: 8444710. DOI: 10.1093/neuonc/noaa059. View

4.
Xu Y, Geng R, Yuan F, Sun Q, Liu B, Chen Q . Identification of differentially expressed key genes between glioblastoma and low-grade glioma by bioinformatics analysis. PeerJ. 2019; 7:e6560. PMC: 6409090. DOI: 10.7717/peerj.6560. View

5.
Zhang Y, Liu Z . STAT1 in cancer: friend or foe?. Discov Med. 2017; 24(130):19-29. View